|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4245 | |
| A61K 39/395 | |||
| A61K 45/06 | |||
| A61P 35/00 |
| (11) | Number of the document | 3102237 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15746743.2 |
| Date of filing the European patent application | 2015-02-03 | |
| (97) | Date of publication of the European application | 2016-12-14 |
| (45) | Date of publication and mention of the grant of the patent | 2020-12-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/014247 |
| Date | 2015-02-03 |
| (87) | Number | WO 2015/119944 |
| Date | 2015-08-13 |
| (30) | Number | Date | Country code |
| 201461935714 P | 2014-02-04 | US |
| (72) |
LEOPOLD, Lance, US
KAUFMAN, David, US
|
| (73) |
Merck Sharp & Dohme Corp.,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, US |
| (54) | COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER |
| COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER |